GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Inventory Turnover

AVANIR Pharmaceuticals (FRA:AV2B) Inventory Turnover : -1.14 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. AVANIR Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2014 was €-0.64 Mil. AVANIR Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2014 was €0.56 Mil. AVANIR Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2014 was -1.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AVANIR Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2014 was 0.02.

AVANIR Pharmaceuticals Inventory Turnover Historical Data

The historical data trend for AVANIR Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Inventory Turnover Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.95 6.51 7.28 4.75

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.94 2.19 2.57 -1.14

AVANIR Pharmaceuticals Inventory Turnover Calculation

AVANIR Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Sep. 2014 is calculated as

Inventory Turnover (A: Sep. 2014 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Sep. 2014 ) / ((Total Inventories (A: Sep. 2013 ) + Total Inventories (A: Sep. 2014 )) / count )
=2.734 / ((0.531 + 0.62) / 2 )
=2.734 / 0.5755
=4.75

AVANIR Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2014 is calculated as

Inventory Turnover (Q: Sep. 2014 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Sep. 2014 ) / ((Total Inventories (Q: Jun. 2014 ) + Total Inventories (Q: Sep. 2014 )) / count )
=-0.644 / ((0.505 + 0.62) / 2 )
=-0.644 / 0.5625
=-1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVANIR Pharmaceuticals  (FRA:AV2B) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AVANIR Pharmaceuticals's Days Inventory for the three months ended in Sep. 2014 is calculated as:

Days Inventory =Average Total Inventories (Q: Sep. 2014 )/Cost of Goods Sold (Q: Sep. 2014 )*Days in Period
=0.5625/-0.644*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AVANIR Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2014 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2014 ) / Revenue (Q: Sep. 2014 )
=0.5625 / 25.379
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

AVANIR Pharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Inventory Turnover
Comparable Companies
XCNQ:CURA TSX:ACB XTER:EVT SHSE:600380 SZSE:000423 XKRX:128940 SHSE:603858 SHSE:600511 SHSE:600566 SHSE:600535 TSE:4555 SHSE:688321 SZSE:000623 SHSE:600521 XLJU:KRKG SHSE:600079 NSE:ALKEM HKSE:02005 HKSE:01558 NSE:AUROPHARMA
Traded in Other Exchanges
N/A
Address
Website
http://www.avanir.com
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines